The strategy of using biologically-targeted therapeutics for cancer has yet to translate into effective treatment of gliomas. The neuro-oncology community is beginning to recognize that phase 0 studies should be performed to account for the impact of the blood-brain-barrier on the ability of a therapeutic to reach its target(s).
https://ift.tt/2s9ZrYx
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου